Urethral Interfractional Geometric and Dosimetric Variations of Prostate Cancer Patients: A Study Using an Onboard MRI

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Aug 1

PMID 35912253

Authors

Jonathan Pham

Ricky R Savjani

Stephanie M Yoon

Tiffany Yang

Yu Gao

Minsong Cao

Peng Hu

Ke Sheng

Daniel A Low

Michael Steinberg

Amar U Kishan

Yingli Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: For a cohort of prostate cancer patients treated on an MR-guided radiotherapy (MRgRT) system, we retrospectively analyzed urethral interfractional geometric and dosimetric variations based on onboard MRIs acquired at different timepoints and evaluated onboard prostatic urethra visualization for urethra-focused online adaptive RT.

Methods: Twenty-six prostate cancer patients were prospectively scanned on a 0.35-T MRgRT system using an optimized T2-weighted HASTE sequence at simulation and final fraction. Two radiation oncologists (RO1 and RO2) contoured the urethras on all HASTE images. The simulation and final fraction HASTE images were rigidly registered, and urethral interobserver and interfractional geometric variation was evaluated using the 95th percentile Hausdorff distance (HD95), mean distance to agreement (MDA), center-of-mass shift (COMS), and DICE coefficient. For dosimetric analysis, simulation and final fraction HASTE images were registered to the 3D bSSFP planning MRI and 3D bSSFP final setup MRI, respectively. Both ROs' urethra contours were transferred from HASTE images for initial treatment plan optimization and final fraction dose estimation separately. Stereotactic body radiotherapy (SBRT) plans, 40 Gy in 5 fractions, were optimized to meet clinical constraints, including urethral V42Gy ≤0.03 cc, on the planning MRI. The initial plan was then forward calculated on the final setup MRI to estimate urethral dose on the final fraction and evaluate urethral dosimetric impact due to anatomy change.

Results: The average interobserver HD95, MDA, COMS, and DICE were 2.85 ± 1.34 mm, 1.02 ± 0.36 mm, 3.16 ± 1.61 mm, and 0.58 ± 0.15, respectively. The average interfractional HD95, MDA, COMS, and DICE were 3.26 ± 1.54 mm, 1.29 ± 0.54 mm, 3.34 ± 2.01 mm, and 0.49 ± 0.18, respectively. All patient simulation MRgRT plans met all clinical constraints. For RO1 and RO2, 23/26 (88%) and 21/26 (81%) patients' final fraction estimated urethral dose did not meet the planned constraint. The average urethral V42Gy change was 0.48 ± 0.58 cc.

Conclusion: Urethral interfractional motion and anatomic change can result in daily treatment violating urethral constraints. Onboard MRI with good visualization of the prostatic urethra can be a valuable tool to help better protect the urethra through patient setup or online adaptive RT.

Citing Articles

Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.

Winter J, Reddy V, Li W, Craig T, Raman S Br J Radiol. 2024; 97(1153):31-40.

PMID: 38263844 PMC: 11027310. DOI: 10.1093/bjr/tqad041.

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation.

Benitez C, Steinberg M, Cao M, Qi X, Lamb J, Kishan A Cancers (Basel). 2023; 15(18).

PMID: 37760626 PMC: 10526919. DOI: 10.3390/cancers15184657.

A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.

Patel K, Rydzewski N, Schott E, Cooley-Zgela T, Ning H, Cheng J Pract Radiat Oncol. 2023; 13(6):540-550.

PMID: 37442430 PMC: 10782822. DOI: 10.1016/j.prro.2023.05.012.

References

Hannan R, Tumati V, Xie X, Cho L, Kavanagh B, Brindle J . Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016; 59:142-151. DOI: 10.1016/j.ejca.2016.02.014. View

Zakian K, Wibmer A, Vargas H, Alberts E, Kadbi M, Mychalczak B . Comparison of Motion-Insensitive T2-Weighted MRI Pulse Sequences for Visualization of the Prostatic Urethra During MR Simulation. Pract Radiat Oncol. 2019; 9(6):e534-e540. PMC: 6832802. DOI: 10.1016/j.prro.2019.06.009. View

Kataria T, Gupta D, Goyal S, Bisht S, Chaudhary R, Narang K . Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach. Br J Radiol. 2016; 89(1068):20160348. PMC: 5604912. DOI: 10.1259/bjr.20160348. View

Ma T, Lamb J, Casado M, Wang X, Basehart T, Yang Y . Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer. 2021; 21(1):538. PMC: 8114498. DOI: 10.1186/s12885-021-08281-x. View

Litzenberg D, Muenz D, Archer P, Jackson W, Hamstra D, Hearn J . Changes in prostate orientation due to removal of a Foley catheter. Med Phys. 2018; 45(4):1369-1378. DOI: 10.1002/mp.12830. View

Brand D, Tree A, Ostler P, van der Voet H, Loblaw A, Chu W . Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019; 20(11):1531-1543. PMC: 6838670. DOI: 10.1016/S1470-2045(19)30569-8. View

Commandeur F, Simon A, Mathieu R, Nassef M, Ospina Arango J, Rolland Y . MRI to CT Prostate Registration for Improved Targeting in Cancer External Beam Radiotherapy. IEEE J Biomed Health Inform. 2016; 21(4):1015-1026. DOI: 10.1109/JBHI.2016.2581881. View

Richardson M, Skehan K, Wilton L, Sams J, Samuels J, Goodwin J . Visualising the urethra for prostate radiotherapy planning. J Med Radiat Sci. 2021; 68(3):282-288. PMC: 8424315. DOI: 10.1002/jmrs.485. View

Takeda T, Tin A, Corradi R, Mamoor M, Benfante N, Sjoberg D . Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens. Eur Urol. 2017; 73(4):488-490. PMC: 6050029. DOI: 10.1016/j.eururo.2017.08.005. View

10.

Zilli T, Jorcano S, Bral S, Rubio C, Bruynzeel A, Oliveira A . Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Cancer Med. 2020; 9(9):3097-3106. PMC: 7196054. DOI: 10.1002/cam4.2966. View

11.

Leeman J, Chen Y, Catalano P, Bredfeldt J, King M, Mouw K . Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys. 2021; 112(1):75-82. DOI: 10.1016/j.ijrobp.2021.06.037. View

12.

Pham J, Savjani R, Gao Y, Cao M, Hu P, Sheng K . Evaluation of T2-Weighted MRI for Visualization and Sparing of Urethra with MR-Guided Radiation Therapy (MRgRT) On-Board MRI. Cancers (Basel). 2021; 13(14). PMC: 8307202. DOI: 10.3390/cancers13143564. View

13.

Tocco B, Kishan A, Ma T, Kerkmeijer L, Tree A . MR-Guided Radiotherapy for Prostate Cancer. Front Oncol. 2020; 10:616291. PMC: 7757637. DOI: 10.3389/fonc.2020.616291. View

14.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

15.

Dekura Y, Nishioka K, Hashimoto T, Miyamoto N, Suzuki R, Yoshimura T . The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy. Radiat Oncol. 2019; 14(1):226. PMC: 6909476. DOI: 10.1186/s13014-019-1424-8. View

16.

Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, Simone A . Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol. 2020; 60(2):215-221. DOI: 10.1080/0284186X.2020.1821090. View

17.

Ma T, Neylon J, Casado M, Sharma S, Sheng K, Low D . Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Radiother Oncol. 2022; 167:203-210. DOI: 10.1016/j.radonc.2021.12.037. View

18.

Pathmanathan A, Schmidt M, Brand D, Kousi E, van As N, Tree A . Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI. J Appl Clin Med Phys. 2019; 20(3):27-36. PMC: 6414142. DOI: 10.1002/acm2.12529. View

19.

Cheung M, Tucker S, Dong L, de Crevoisier R, Lee A, Frank S . Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67(4):1059-65. PMC: 2081969. DOI: 10.1016/j.ijrobp.2006.10.042. View

20.

Waterman F, Dicker A . Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the postimplant CT scan. Med Phys. 2000; 27(3):448-51. DOI: 10.1118/1.598912. View